alxoncology.com - ALXO Income before deduction of interest, taxes and amortization

Graphic logo of alxoncology.com (ALXO)

ALX Oncology Holdings (ALXO) is expanding its oncology presence through efivropacept, overcoming certification complexities and patent barriers. Monitoring of EBITDA_Co demonstrates the financial resilience of this strategy, where the value of 0.00 characterizes this level of operational efficiency. Aggressive clinical trials targeting CD47 signal blocking confirm the company's innovative potential in developing breakthrough cancer immunotherapy methods.

Profit before payment of interest, taxes and amortization: ALX Oncology (ALXO) for 11/23/2025 - 11/17/2026

alxoncology.com - analytical breakdowns and key metrics (ALXO)

- market value and analyst target forecast:
Analysis of all company metrics:alxoncology.com - ALXO
Mass-produced product of ALX Oncology Holdings

To verify the credit quality of ALX Oncology Holdings (ALXO), the analyst utilizes the EBITDA_Co assessment, which measures operating cash flow before interest and taxes to identify the actual efficiency of the business. Since the biotechnology sector relies on R&D and capital burn, the lack of positive momentum on the chart confirms the company's dependence on reserves, turning this indicator into a marker of operational deficit.

Competitors of ALX Oncology Holdings (ALXO)

ImmunityBio (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (Janux Therapeutics, Inc.)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization tangotx.com|Operating profit before deduction of amortization iovance.com (IOVA)|Profit before payment of interest, taxes and amortization Immatics NV (IMTX)|Operating profit before deduction of amortization Xencor Corp XNCR|Compass Therapeutics Inc - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Inc. REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (innate-pharma.com) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen Ltd. (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma, Inc.)|cuebiopharma.com (CUE) - Profit before interest, taxes and amortization|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus Pharma - Income before deduction of interest, taxes and amortization|LVTX (Lava Tx) - Operating profit EBITDA|Operating profit EBITDA NextCure Inc|Profit before payment of interest, taxes and amortization leaptx.com (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Biologics (TOVX) - Profit before interest, taxes and amortization|gritstonebio.com - Operating profit EBITDA|KA (Kineta) - Operating profit before amortization|NEXI: Operating profit EBITDA|Turnstone Biologics Corporation (TSBX) - Operating profit EBITDA|VCNX (vaccinex.com) - Operating profit EBITDA|HARP: Income before deduction of interest, taxes and amortization